Cargando…

Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy

To evaluate the efficacy and safety of telbivudine (LdT) and tenofovir (TDF) for preventing hepatitis B virus (HBV) vertical transmission for HBV-positive pregnant women. Pregnant women (n = 145) from January 2013 to June 2017 were enrolled when they met inclusion criteria, which included HBV DNA ≥1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Jianyong, Zheng, Caixia, Li, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455986/ https://www.ncbi.nlm.nih.gov/pubmed/30946367 http://dx.doi.org/10.1097/MD.0000000000015092

Ejemplares similares

Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
por: Sun, Weihui, et al.
Publicado: (2017)

Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
por: Ren, Cuicui, et al.
Publicado: (2020)

Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis
por: Wu, Xiaolu, et al.
Publicado: (2016)

Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus
por: Zhu, Bo, et al.
Publicado: (2021)

Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis
por: Liu, Min-Hui, et al.
Publicado: (2013)

Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy
por: Tan, Zhangmin, et al.
Publicado: (2016)

The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
por: Deng, Min, et al.
Publicado: (2012)

A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B
por: Jindal, Ankur, et al.
Publicado: (2019)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load
por: Chen, Jun-Ze, et al.
Publicado: (2017)

Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine, Telbivudine, and Tenofovir: A Meta-analysis
por: Sali, Shahnaz, et al.
Publicado: (2019)

Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study
por: Cai, Mengzhi, et al.
Publicado: (2019)

Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads
por: Lin, Yayun, et al.
Publicado: (2018)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
por: Ying, Yue, et al.
Publicado: (2018)

Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa
por: Mokaya, Jolynne, et al.
Publicado: (2019)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

The effectiveness of 20 μg hepatitis B vaccine used for the prevention of HBV vertical transmission
por: Yonghao, Guo, et al.
Publicado: (2022)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
por: Manik, Abul H, et al.
Publicado: (2021)

Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
por: Zhang, Hua, et al.
Publicado: (2014)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
por: Piratvisuth, Teerha, et al.
Publicado: (2016)

Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
por: Krastev, Zahari, et al.
Publicado: (2016)

Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study
por: Li, Zhenhua, et al.
Publicado: (2020)

Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
por: Leung, Nancy W. Y., et al.
Publicado: (2014)

Hepatitis B virus genotype is an independent prognostic factor of telbivudine and tenofovir treatment in hepatitis B surface antigen‐positive pregnant women
por: Zhang, Baofang, et al.
Publicado: (2021)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Clinicopathological Features of Telbivudine-Associated Myopathy
por: Ambang, Tomica, et al.
Publicado: (2016)

Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis
por: Price, Huw, et al.
Publicado: (2013)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
por: Han, Li-fen, et al.
Publicado: (2019)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
por: Pan, Calvin Q., et al.
Publicado: (2021)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
por: Liu, Qing-Min, et al.
Publicado: (2021)

Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24
por: Hsu, Chao Wei, et al.
Publicado: (2012)

Myotoxicity of telbivudine in pre-existing muscle damage
por: Finsterer, Josef, et al.
Publicado: (2010)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
por: Dobard, Charles W, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ldj6hm9ktbhgbfccmg2122o05n